3SBio Acquires China Rights to Numab Immunotherapy
publication date: Dec 17, 2021
3SBio (HK:1530) of Shenyang expanded its partnership with Zurich's Numab Therapeutics by acquiring China rights to Numab's multivalent mesothelin (MSLM)-targeting CD3 T cell engager, an immunotherapy. The candidate consists of four antibody variable domain fragments directed against MSLN, CD3 and human serum albumin. MSLN is commonly expressed in several types of tumor cells including mesothelioma, lung, biliary, ovarian, breast and pancreatic cancer. In 2019, 3SBio invested $15 million in Numab for options to develop up to five novel Numab immunotherapy candidates. More details....
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.